An 11% five-year benefit against prostate cancer spread came with added treatment for men with very high test scores.
Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.
How this was made
The 30-second read
Why it matters
The announcement could accelerate adoption and drive near‑term sales, but actual market reaction will depend on payer acceptance.
Market read
First public disclosure of predictive data for a prostate cancer test; likely to affect Veracyte's valuation and the broader diagnostics sector.
What to watch
Reimbursement decisions and the upcoming PREDICT‑RT trial results could moderate impact.
Background
Veracyte is a molecular diagnostics firm whose Decipher prostate test is already used in high‑risk disease; this new evidence expands its clinical utility.
Ticker impact
Veracyte announced new predictive data from the STAMPEDE trial showing its Decipher test can identify prostate cancer patients who benefit from adding abiraterone to ADT.
likely upward pressure as investors price in expanded test utility
First disclosure of Level 1B predictive data; supports product adoption and could drive near‑term revenue growth.
Market effects
Strengthens the prostate‑cancer diagnostics segment and may prompt competitors to seek similar data.
U.S. biotech investors may re‑price related diagnostic companies.
Adds to global oncology testing landscape, potentially influencing European and Asian markets.
Counterpoint
If the data does not translate into payer coverage, the stock may not benefit.
Key entities
- companyVeracyte, Inc.
US‑listed diagnostics company (NASDAQ: VCYT).
- clinical_trialSTAMPEDE trial
Phase III prostate cancer trial providing the data.
